Abbott and Eisai launch of PDER drug Lipacreon in Japan

Following regulatory approval earlier this year (The Pharma Letter April 27), the Japanese subsidiary of US health care giant Abbott Laboratories (NYSE: ABT)  and Japan’s Eisai (TYO: 4523) yesterday launched their pancreatic digestive enzyme replacement drug Lipacreon (pancrelipase) capsules 150mg and Lipacreon granules 300mg sachets 30 in Japan.

Abbott Japan received approval to manufacture and market Lipacreon in Japan as a pancreatic digestive enzyme replacement in patients with pancreatic exocrine insufficiency (PEI) on April 22 of this year, with the drug being registered on the National Health Insurance Drug Price List on July 19. Eisai will market the Lipacreon and ensure the provision of information on its proper use.

Drug already sold in 80 countries, under names such as Creon and Kreon